Details for Patent: 7,511,131

Which drugs does patent 7,511,131 protect, and when does it expire?

Patent 7,511,131 protects KYNAMRO and is included in one NDA.

This patent has forty-five patent family members in eleven countries.

Summary for Patent: 7,511,131

Title:	Antisense modulation of apolipoprotein B expression
Abstract:	Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
Inventor(s):	Crooke; Roseanne M. (Carlsbad, CA), Graham; Mark (San Clemente, CA), Freier; Susan M. (San Diego, CA)
Assignee:	Genzyme Corporation (Cambridge, MA)
Application Number:	10/712,795
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,511,131
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation;

Drugs Protected by US Patent 7,511,131

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013		DISCN	Yes	No				Y

International Family Members for US Patent 7,511,131

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002326481
Australia	2003237875
Australia	2003294281
Canada	2455228